|Over a week ago|
X4 patent strengthens commercial outlook for mavorixafor, says Roth » 09:5402/1302/13/20
Roth Capital analyst…
Roth Capital analyst Zegbeh Jallah reiterated her Buy rating on X4 Pharmaceuticals after the company announced it was issued a new composition of matter patent for mavorixafor. The patent is expected to provide exclusivity through 2038, said Jallah, who added that she views this particular patent issuance as material since she believes it gives further reassurance around the future commercial outlook of X4's lead product candidate.
X4 Pharmaceuticals issued X4P-001 exclusivity patent from USPTO » 08:0402/1202/12/20
X4 Pharmaceuticals announced that the United States Patent and Trademark Office, or USPTO, has issued United States Patent No. 10,548,889, which is expected to provide exclusivity of X4's lead therapeutic candidate, mavorixafor, X4P-001, through 2038.
|Over a month ago|
X4 Pharmaceuticals initiated with a Buy at H.C. Wainwright » 07:0601/0701/07/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of X4 Pharmaceuticals with a Buy rating and $22 price target. is a clinical-stage company developing novel therapies targeting the key immune cell chemokine receptor, CXCR4, for the treatment of rare primary immunodeficiency diseases and cancers, says the analyst. X4 is collaborating with multiple organizations to improve the awareness and diagnosis of WHIM syndrome and plans to provide an update of the estimated patient population in Q1 of 2020, which could be a major catalyst, adds the analyst.
X4 Pharmaceuticals study initiation a positive sign, says Roth Capital » 12:2512/3012/30/19
Roth Capital analyst…
Roth Capital analyst Zegbeh Jallah maintained a Buy rating and $20 price target on X4 Pharmaceuticals after the company announced the initiation of a Phase 1b study of its lead drug, mavorixafor, in Waldenstrom's macroglobulinemia. The analyst said he likes that they "squeezed in this initiation before year-end," staying in-line with Q4 guidance and a second half 2020 data readout, and added that this should help "build investors' confidence in mavorixafor's market-opportunity."
X4 Pharmaceuticals initiates Phase 1b trial of mavorixafor/ibrutinib combo » 08:3112/3012/30/19
X4 Pharmaceuticals announced the initiation of a Phase 1b clinical trial of mavorixafor in combination with ibrutinib for the treatment of Waldenstrom's macroglobulinemia, a rare form of non-Hodgkin's lymphoma. Mavorixafor, X4's lead therapeutic candidate, is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4.
X4 Pharmaceuticals initiated with an Outperform at Oppenheimer » 06:5112/2312/23/19
Oppenheimer analyst Leland Gershell initiated coverage of X4 Pharmaceuticals with an Outperform rating and $20 price target. The company's lead candidate mavorixafor, a first-in-class oral CXCR4 antagonist with a "favorable" safety profile, is positioned to address several rare, chronic disorders stemming from immunodeficiency that currently lack effective options, Gershell tells investors in a research note. The analyst expects an initial approval for WHIM syndrome and is "cautiously optimistic" on a role in Waldenstrom's macroglobulinemia.
X4 Pharmaceuticals initiated with a Buy at Roth Capital » 05:1012/1812/18/19
Roth Capital analyst…
Roth Capital analyst Zegbeh Jallah initiated coverage of X4 Pharmaceuticals with a Buy rating and $20 price target. The analyst has "strong conviction" around the clinical and commercial outlook of X4's lead CXCR4 antagonist, mavorixafor, which is being developed for several rare diseases. The company's "robust" pipeline of optimized CXCR4 modulators could offer improved benefits across a broader range of diseases, Jallah tells investors in a research note. She believes mavorixafor's potential is "much more promising" than investors may give it credit for.
X4 Pharmaceuticals upgraded to Buy from Neutral at Citi » 09:4812/0912/09/19
Citi upgraded X4…
Citi upgraded X4 Pharmaceuticals to Buy from Neutral.
Fly Intel: Top five analyst initiations » 10:0312/0512/05/19
FB, HES, XFOR, KSU, WERN
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Facebook (FB) initiated with a Reduce at HSBC. 2. Hess Corp. (HES) initiated with a Market Perform at Cowen. 3. X4 Pharmaceuticals (XFOR) initiated with a Buy at B. Riley FBR. 4. Kansas City Southern (KSU) initiated with a Neutral at Goldman Sachs. 5. Werner (WERN) initiated with a Buy at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
X4 Pharmaceuticals initiated with a Buy at B. Riley FBR » 04:4412/0512/05/19
B. Riley FBR initiated…
B. Riley FBR initiated coverage of X4 Pharmaceuticals with a Buy rating and $25 price target.